EUVIMEDEUVIMED entdecken
Crossref

The ambivalence toward neuropsychology in dementia research, diagnosis, and drug development: Myths and misconceptions

María K Jónsdóttir, John Harrison, Kristín I Hannesdóttir

Alzheimer's & Dementia · 2023-05 · 19 (5) · 2175-2181

DOI: 10.1002/alz.12909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 13.01.2023. Verfasst von María K Jónsdóttir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Reykjavík University, Reykjavík, Iceland. Hauptthemen laut MEDLINE: Dementia, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical assessment remains the gold standard for diagnosing dementia, monitoring progression, and conducting clinical research. Biomarkers hold promise for targeted therapeutic approaches, selection of participants in clinical trials, and direct physiological efficacy readouts. However, the anchoring of biomarker research to clinical symptomatology is often based on short and insensitive cognitive screening. This gives the impression that cognitive symptoms occur relatively late and that their progression in the early stages of the disease is slow. A thorough cognitive assessment is a powerful tool and has a key role in the accurate and early diagnosis of dementia. It is very different from the cognitive testing usually seen in biomarker research and drug development. Yet the distinction between these approaches is unclear to many. This paper highlights the misconceptions around cognitive research in dementia and suggests a way forward to facilitate biomarker and drug development through the improved utility of cognitive assessment tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DementiaAlzheimer DiseaseCognitive DysfunctionHumansNeuropsychologyBiomarkersNeuropsychological Tests

Stichwörter der Autor:innen

cognitive assessmentcognitive endpointscognitive screeningdementianeuropsychological assessment

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Reykjavík University, Reykjavík, Iceland.
  • Landspitali - The National University Hospital of Iceland (Memory Clinic), Reykjavík, Iceland.
  • Metis Cognition Ltd., Kilmington Common Wiltshire, UK.
  • Alzheimercentrum, Amsterdam, the Netherlands.
  • Institute of Psychiatry, Psychology & Neuroscience, KCL, London, UK.
  • Novartis Institute of Biomedical Research, Cambridge, Massachusetts, USA.

Zitieren

APA

Jónsdóttir, M. K., Harrison, J., & Hannesdóttir, K. I. (2023). The ambivalence toward neuropsychology in dementia research, diagnosis, and drug development: Myths and misconceptions. Alzheimer's & Dementia, 19(5), 2175-2181. https://doi.org/10.1002/alz.12909

Vancouver

Jónsdóttir MK, Harrison J, Hannesdóttir KI. The ambivalence toward neuropsychology in dementia research, diagnosis, and drug development: Myths and misconceptions. Alzheimer's & Dementia. 2023;19(5):2175-2181. doi:10.1002/alz.12909

BibTeX
@article{Jnsdttir2023,
  author = {Jónsdóttir, María K and Harrison, John and Hannesdóttir, Kristín I},
  title = {The ambivalence toward neuropsychology in dementia research, diagnosis, and drug development: Myths and misconceptions},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {5},
  pages = {2175--2181},
  doi = {10.1002/alz.12909}
}
Kostenlos starten →